(Adnkronos) - Guselkumab, il primo anticorpo monoclonale completamente umano diretto selettivamente contro la subunità p19 dell’IL-23, continua a dimostrarsi una terapia efficace e sicura sia nella colite ulcerosa sia nella malattia di Crohn. Importanti risultati sono stati presentati da Johnson & Johnson in occasione del Congresso dell’Italian Group of Inflammatory Bowel Disease
Category
🗞
NewsTranscript
00:00In Italy, 250,000 people are forced to live with inflammatory and chronic intestinal diseases.
00:11For them, a new hope comes from Guselcumab, a biological treatment that selectively inhibits a subunit of Interleukin-23,
00:20which continues to prove to be an effective and safe therapy both in ulcerative colitis and Crohn's disease.
00:26Surely, Guselcumab represents a step forward, a step towards the personalization of the treatment.
00:34The flexibility, both in terms of dosage, but above all in terms of supply,
00:40with the availability both in subcutaneous and endovenous form,
00:45will allow our patients to choose the treatment according to their needs.
00:51And this is a very important factor that will bring us closer and closer to be able to treat patients
00:58on the basis of their needs in the field of personalized medicine.
01:04It is also important to underline how the treatment of Guselcumab
01:09is a treatment that is able to achieve goals that are more and more complicated, more and more ambitious.
01:16There are composite goals such as endoscopy in association with histology,
01:22which is fundamental especially in ulcerative colitis,
01:25and how the maintenance of these goals is long-term.
01:29Johnson & Johnson has presented the important news
01:32at the Riccione Congress of the Italian Group of Inflammatory Bowel Disease.
01:37In the Quasar study, which has evaluated the efficacy and safety of Guselcumab
01:42in patients with moderately serious ulcerative colitis,
01:46it has been shown that after a year of treatment,
01:49up to 35% of patients with ulcerative colitis reached a very important endpoint,
01:55which was that of mucosal healing.
01:57Endoscopic remission, in addition to that clinic and even more than that clinic,
02:01is very important to define the long-term outcomes of ulcerative colitis,
02:06as it has been shown that up to 70% of patients in the long term
02:11who reach an endoscopic remission remain free from recidivism.
02:16The equally important aspect is that this result has been documented
02:21as positive, significantly positive,
02:24also in patients who had previously failed advanced therapies
02:29and not only in naive patients to biopharmaceuticals.
02:33Guselcumab is being evaluated by the European Medicinal Agency
02:37for the treatment of adult patients with ulcerative colitis
02:40and Crohn's disease from moderate to serious.
02:43In relation to the record studies on Crohn's disease,
02:46Guselcumab can be positioned for patients who are bio-naive or bio-exposed.
02:52The effectiveness of 70% from the point of view of clinical remission to one year
02:57certainly represents a big target for our patients with Crohn's disease.